Reshoring Pharmaceutical Production: Are Buy America Laws Enough?
By Kenneth Rapoza, Industry Analyst, CPA President Trump and many members of Congress are talking about reshoring pharmaceutical production. We look at the benefits of
By Kenneth Rapoza, Industry Analyst, CPA President Trump and many members of Congress are talking about reshoring pharmaceutical production. We look at the benefits of
CPA’s Take: This is excellent. Finally, import competition is being accepted in agriculture as harmful to domestic producers. Washington, DC — The Office of the U.S.
By Kenneth Rapoza, Industry Analyst, CPA The latest Chinese company additions to the Commerce Department’s Entity List shows the growing influence of national security in
CPA’s Take: CPA supports efforts to remove Chinese stocks from the US stock market because they do not let us access their audited financial records. It
CPA’s Take: The battle within the Biden campaign on trade between the Wall Street globalists and the fair traders is real. The former vice president
By Kenneth Rapoza, Industry Analyst, CPA Joe Biden’s trade team has the right ideas on China. Here are some standouts we note in his Made
By Kenneth Rapoza, Industry Analyst, CPA Washing machine prices rose in 2018 and we are all reminded that tariffs are to blame. But they’ve been
CPA’s Take: Very bad! The IMF has failed to stop currency manipulation. The US has acted with a modest regulation that defines when we can
CPA’s Take: When Kamala Harris was running for president, this is what she said about trade. Democratic candidate for President; California Senator [December 15, 2019
Editor’s Note: CPA submitted testimony to the Senate Finance Committee relating to WTO reform. Our testimony points out the fundamental flaws in the WTO, suggests reform